Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
5.68
Oct 30 • 3:59 PM ET Dollar change-0.10 Percentage change(-1.73%)
Aftermarket Close
5.80
Aftermarket • 7:59 PM ET Dollar change+0.12 Percentage change(2.11%)
Oct 29, 9:31 AMPediatric Aquadex study news extends as Nuwellis jumps 23% into the open
Index
-
Market Cap
3.07M
Enterprise Value
-0.64M
Income
-11.32M
Sales
9.01M
Book/sh
-32.20
Cash/sh
7.25
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
38
IPO
Feb 16, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
0.34
P/B
-
P/C
0.78
P/FCF
-
EV/EBITDA
-
EV/Sales
-0.07
Quick Ratio
1.54
Current Ratio
1.97
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / No
EPS (ttm)
-1224.57
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
94.09% 88.99%
Sales past 3/5Y
-1.08% 2.14%
EPS Y/Y TTM
88.88%
Sales Y/Y TTM
8.36%
EPS Q/Q
98.75%
Sales Q/Q
14.14%
Insider Own
35.96%
Insider Trans
0.00%
Inst Own
0.43%
Inst Trans
5.87%
ROA
-123.57%
ROE
-609.44%
ROIC
-
Gross Margin
69.69%
Oper. Margin
-142.87%
Profit Margin
-125.57%
SMA20
8.26%
SMA50
-14.47%
SMA200
-97.62%
Trades
Shs Outstand
0.54M
Shs Float
0.35M
52W High
1556.07 -99.63%
52W Low
2.52 125.00%
Volatility
38.41% 19.22%
ATR (14)
1.00
RSI (14)
47.83
Beta
0.04
Rel Volume
0.29
Avg Volume
1.09M
Volume
311,446
Perf Week
95.94%
Perf Month
-15.74%
Perf Quarter
-60.80%
Perf Half Y
-98.31%
Perf YTD
-98.96%
Perf Year
-99.53%
Perf 3Y
-100.00%
Perf 5Y
-100.00%
Perf 10Y
-100.00%
Prev Close
5.78
Price
5.68
Change %
-1.73%
Consensus
Strong Buy
Avg. Price Target
$145,530.00
Implied Upside
+2,562,048.0%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 29, 2024Initiated
RROTH MKM
Buy$17+199.3%
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
PresidentMr. Michael Kendrick McCormick
Senior VPMr. Neil P. Ayotte Esq.
CFOMs. Carisa Schultz
Vice PresidentMs. Kim Anderson
Chief Technology OfficerMr. David Lerner